Continuous monitoring of a monoclonal antibody by size exclusion chromatography reveals a correlation between system suitability parameters and column aging

被引:0
作者
Wu, Kai-Wei [1 ]
Chen, Tse-Hong [2 ]
Yang, Teng-Chieh [2 ,3 ]
Wang, Shao-Chun [2 ]
Shameem, Mohammed [2 ]
Graham, Kenneth S. [2 ]
机构
[1] Univ Mississippi, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA
[2] Regeneron Pharmaceut Inc, Formulat Dev Grp, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Alexion Pharmaceut Inc, Injectable Drug Prod Dev, 100 Coll St, New Haven, CT 06510 USA
关键词
Size exclusion chromatography; System suitability; Column aging; Column robustness; Monoclonal antibody; Biotherapeutics; PROTEIN AGGREGATION; DESIGN; IMPACT;
D O I
10.1016/j.jpba.2023.115622
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Size exclusion chromatography (SEC) is a foundational analytical method to assess product purity of biological molecules. To ensure accurate and reproducible data that meet regulatory agency standards, it is critical to monitor the chromatographic column with efficient and continuous approaches. In this study, 19 SEC columns (Waters Acquity BEH200) were evaluated using an in-house monoclonal antibody made at Regeneron. System suitability parameters (SSPs) were used to monitor the performance of the SEC assay, including USP resolution, USP plate count, USP tailing factor, asymmetry factor, elution time, peak width, and peak height. A general linear model was built and revealed that elution time, peak width, asymmetry factor, and tailing factor increased with injection number, while peak height, resolution, and plate count decreased. After 1000 injections, tailing factor and peak width increased by more than 10%, while resolution and plate count decreased by more than 10% from their respective starting values.
引用
收藏
页数:6
相关论文
共 27 条
[1]   Impact of mAb Aggregation on Its Biological Activity: Rituximab as Case Study [J].
Bansal, Rohit ;
Dash, Rozaleen ;
Rathore, Anurag S. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (09) :2684-2698
[2]   System suitability in bioanalytical LC/MS/MS [J].
Briscoe, Chad J. ;
Stiles, Mark R. ;
Hage, David S. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 44 (02) :484-491
[3]  
Chu TW, 2020, LC GC EUR, V33, P27
[4]   Setting system suitability criteria for detectability in high-performance liquid chromatography methods using signal-to-noise ratio statistical tolerance intervals [J].
Coleman, J ;
Wrzosek, T ;
Roman, R ;
Peterson, J ;
McAllister, P .
JOURNAL OF CHROMATOGRAPHY A, 2001, 917 (1-2) :23-27
[5]   Defining a system suitability limit to decide on column deterioration and to facilitate column transfers in chiral supercritical fluid chromatography [J].
Declerck, Sven ;
Vander Heyden, Yvan ;
Mangelings, Debby .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2020, 412 (24) :6221-6230
[6]  
Fekete S., 2018, AM PHARM REV, P1
[7]   Theory and practice of size exclusion chromatography for the analysis of protein aggregates [J].
Fekete, Szabolcs ;
Beck, Alain ;
Veuthey, Jean-Luc ;
Guillarme, Davy .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 101 :161-173
[8]   Critical evaluation of fast size exclusion chromatographic separations of protein aggregates, applying sub-2 μm particles [J].
Fekete, Szabolcs ;
Ganzler, Katalin ;
Guillarme, Davy .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 78-79 :141-149
[9]   Developments and Challenges for mAb-Based Therapeutics [J].
Goswami, Sumit ;
Wang, Wei ;
Arakawa, Tsutomu ;
Ohtake, Satoshi .
ANTIBODIES, 2013, 2 (03) :452-500
[10]   The Increasingly Human and Profitable Monoclonal Antibody Market [J].
Grilo, Antonio L. ;
Mantalaris, A. .
TRENDS IN BIOTECHNOLOGY, 2019, 37 (01) :9-16